Posts

Smart Cancer Resources & Research Guide 2026: A Patient-First Map of Diagnosis, Biomarkers, Treatment, Immunotherapy, Resistance & Integrative Oncology

Image
OneDayMD Cancer Resource Library · Network Index · Published September 17, 2026 · Last reviewed and updated September 18, 2026 (v1.1) Cancer information is no longer confined to a single textbook, treatment guideline, or hospital website — and cancer guides should not be limited to oncologists. Modern oncology now spans pathology, staging, molecular biomarkers, precision medicine, prevention, surgery, radiation, chemotherapy, targeted therapy, immunotherapy, cellular therapy, cancer metabolism, treatment resistance, supportive care, and clinical research. This OneDayMD guide brings those subjects together in one navigable resource. Rather than hundreds of disconnected articles, it offers a pathway through the evidence and links directly to deeper OneDayMD, SmartCancer, and Cancer Advisor resources. Quick Answer This page is a map, not a single treatment guide — it connects the OneDayMD network's cancer content by the question you're actually asking. Newly diagnosed...
Post a Comment
Read more

Ivermectin, Fenbendazole & Mebendazole for Cancer: 2026 Evidence Guide

Image
A Master Guide & Reference — Evidence, Mechanisms, Clinical Trials, Case Series, Safety, and Protocols By Dr. Frank Yap, MD · Originally published July 2025 · Reviewed and substantially updated September 2026 Quick Answer Ivermectin, fenbendazole, mebendazole, and niclosamide are antiparasitic drugs with laboratory and animal evidence of anticancer activity, plus a growing body of patient-reported case reports. None of the four is an approved or established cancer treatment.  Mebendazole and niclosamide have gone further into human oncology trials than fenbendazole, but results remain mixed or inconclusive. This guide organizes the mechanistic evidence, clinical trial data, 760+ compiled case reports, safety findings, and the updated Joe Tippens Protocol into one evidence-tiered reference — with the regulatory and safety picture current as of September 2026. Table of Contents Front Matter Introduction: The Joe Tippens Story Part I — The Case for Drug Repurposing...
Post a Comment
Read more

Cancer Treatment Resistance Atlas: A Biomarker, Mechanism & Next-Treatment Matrix (2026)

Image
Updated: September 2026  |  Focus: Cancer Resistance, Precision Oncology, Biomarkers, Tumor Evolution and Treatment Sequencing Why do cancer treatments stop working? Sometimes a cancer is resistant before treatment begins. In other cases, treatment initially works but the disease later progresses. This treatment resistance can arise through genetic evolution, tumor heterogeneity, pathway rewiring, changes in cell state, altered drug transport, DNA-repair mechanisms, immune escape and interactions within the tumor microenvironment. The Cancer Treatment Resistance Atlas organizes these complex relationships into a practical framework: Cancer Type → Biomarker → Treatment → Response → Resistance → Mechanism → Resistance Biomarker → Testing → Next-Treatment Strategy Modern cancer research increasingly recognizes resistance as a dynamic, evolutionary process rather than a single defect. A 2025 Nature Reviews Cancer roadmap from the National C...
Post a Comment
Read more

Archive

Show more